



Press release

Stockholm, 21 December 2020

## Bactiguard expands in Europe

**Bactiguard enters a new partnership with Libera Medica S.L for Spain. The collaboration is based on an exclusive distribution agreement for Bactiguard's portfolio for infection prevention (BIP), with products for the urinary tract, blood stream and respiratory tract.**

Libera Medica is a family-owned business, based in Madrid. The company has a strong focus on infection prevention, marketing and sales of medical devices and equipment in all Spanish regions.

The partnership is a major step in Bactiguard's European expansion, as Spain has a population of 46 million people and is one of the largest countries in Europe.

"Libera Medica has solid competence and experience in marketing solutions for infection prevention to customers all over Spain. We are convinced that they are the right partner for promoting the Bactiguard brand and strengthen our position in Spain", says Cecilia Edström, CFO.

"Hospital acquired infections are a global burden and antibiotic resistance is a growing concern, more relevant than ever in light of the on-going Corona pandemic. We offer innovative products and services, with the aim of improving the safety of patients and caregivers. We are certain that the Bactiguard technology will change the market dynamics of infection control in for example intensive care settings. Therefore, we are very enthusiastic about the future prospects of this collaboration. Together we will continue our work to break the chain of infections. We feel very honoured to represent Bactiguard," says Javier Vázquez, General Director of Libera Medica S.L.

**For further information, please contact:**

Jonas Östregård, Head of Sales Europe, mobile +46 70 521 13 88

**About Bactiguard**

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard's coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary



catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention.

Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia.

Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard at [www.bactiguard.com](http://www.bactiguard.com)